CR20230323A - Quinolinas y azaquinolinas como inhibidores de cd38 - Google Patents
Quinolinas y azaquinolinas como inhibidores de cd38Info
- Publication number
- CR20230323A CR20230323A CR20230323A CR20230323A CR20230323A CR 20230323 A CR20230323 A CR 20230323A CR 20230323 A CR20230323 A CR 20230323A CR 20230323 A CR20230323 A CR 20230323A CR 20230323 A CR20230323 A CR 20230323A
- Authority
- CR
- Costa Rica
- Prior art keywords
- inhibitors
- azaquinolines
- quinolines
- cancer
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163143245P | 2021-01-29 | 2021-01-29 | |
| PCT/US2022/014221 WO2022165114A1 (en) | 2021-01-29 | 2022-01-28 | Quinolines and azaquinolines as inhibitors of cd38 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20230323A true CR20230323A (es) | 2023-10-02 |
Family
ID=80446310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20230323A CR20230323A (es) | 2021-01-29 | 2022-01-28 | Quinolinas y azaquinolinas como inhibidores de cd38 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11952377B2 (enExample) |
| EP (2) | EP4284511B1 (enExample) |
| JP (2) | JP7777596B2 (enExample) |
| KR (1) | KR20230141799A (enExample) |
| CN (1) | CN117580829A (enExample) |
| AR (1) | AR124718A1 (enExample) |
| AU (1) | AU2022212035A1 (enExample) |
| BR (1) | BR112023014898A2 (enExample) |
| CA (1) | CA3208851A1 (enExample) |
| CL (2) | CL2023002163A1 (enExample) |
| CO (1) | CO2023009803A2 (enExample) |
| CR (1) | CR20230323A (enExample) |
| DO (1) | DOP2023000142A (enExample) |
| EC (1) | ECSP23056223A (enExample) |
| ES (1) | ES3042412T3 (enExample) |
| HR (1) | HRP20251111T1 (enExample) |
| HU (1) | HUE072981T2 (enExample) |
| IL (1) | IL304466A (enExample) |
| JO (1) | JOP20230160A1 (enExample) |
| MX (1) | MX2023008701A (enExample) |
| PE (1) | PE20232047A1 (enExample) |
| PL (1) | PL4284511T3 (enExample) |
| RS (1) | RS67253B1 (enExample) |
| TW (1) | TW202241418A (enExample) |
| WO (1) | WO2022165114A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022001019A (es) | 2019-07-31 | 2022-02-22 | Ribon Therapeutics Inc | Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38). |
| WO2024217995A1 (en) | 2023-04-20 | 2024-10-24 | Syngenta Crop Protection Ag | Pesticidally active dihydropyridinone derivatives |
| WO2026000074A1 (en) * | 2024-06-25 | 2026-01-02 | Welnx Company Inc. | Use of cd38 inhibitors for reducing th2 inflammation |
| WO2026075971A1 (en) | 2024-10-01 | 2026-04-09 | Neolaia Inc. | Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors |
| CN119775288B (zh) * | 2024-12-31 | 2025-10-10 | 浙江工业大学 | 一种cd38抑制化合物及应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2646020B1 (en) | 2010-12-01 | 2016-09-21 | Glaxosmithkline LLC | Indoles |
| CN104039956A (zh) | 2011-11-04 | 2014-09-10 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | 治疗方法 |
| EA201591746A1 (ru) * | 2013-03-14 | 2016-08-31 | КОНВЕРДЖЕН ЭлЭлСи | Способы и композиции для ингибирования бромодомен-содержащих белков |
| KR20170090478A (ko) | 2014-12-03 | 2017-08-07 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | Cd38 억제제 및 치료 방법 |
| WO2017053604A1 (en) | 2015-09-23 | 2017-03-30 | The Regents Of The University Of California | Potent antiviral pyrazolopyridine compounds |
| WO2018151830A1 (en) | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
| EP3434692A1 (en) | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
| MX2022001019A (es) | 2019-07-31 | 2022-02-22 | Ribon Therapeutics Inc | Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38). |
| US20230025807A1 (en) | 2019-10-30 | 2023-01-26 | Mitobridge Inc. | Cd38 inhibitors |
| CN115697985B (zh) | 2020-04-07 | 2025-01-21 | 米托布里奇公司 | Cd38抑制剂 |
-
2022
- 2022-01-28 HR HRP20251111TT patent/HRP20251111T1/hr unknown
- 2022-01-28 CR CR20230323A patent/CR20230323A/es unknown
- 2022-01-28 HU HUE22704226A patent/HUE072981T2/hu unknown
- 2022-01-28 EP EP22704226.4A patent/EP4284511B1/en active Active
- 2022-01-28 BR BR112023014898A patent/BR112023014898A2/pt unknown
- 2022-01-28 WO PCT/US2022/014221 patent/WO2022165114A1/en not_active Ceased
- 2022-01-28 US US17/586,939 patent/US11952377B2/en active Active
- 2022-01-28 PE PE2023002190A patent/PE20232047A1/es unknown
- 2022-01-28 MX MX2023008701A patent/MX2023008701A/es unknown
- 2022-01-28 AU AU2022212035A patent/AU2022212035A1/en active Pending
- 2022-01-28 PL PL22704226.4T patent/PL4284511T3/pl unknown
- 2022-01-28 JP JP2023544674A patent/JP7777596B2/ja active Active
- 2022-01-28 RS RS20250955A patent/RS67253B1/sr unknown
- 2022-01-28 KR KR1020237027359A patent/KR20230141799A/ko active Pending
- 2022-01-28 TW TW111103880A patent/TW202241418A/zh unknown
- 2022-01-28 CN CN202280022060.6A patent/CN117580829A/zh active Pending
- 2022-01-28 ES ES22704226T patent/ES3042412T3/es active Active
- 2022-01-28 EP EP25188747.7A patent/EP4674415A3/en active Pending
- 2022-01-28 AR ARP220100173A patent/AR124718A1/es unknown
- 2022-01-28 CA CA3208851A patent/CA3208851A1/en active Pending
-
2023
- 2023-07-13 IL IL304466A patent/IL304466A/en unknown
- 2023-07-20 JO JOJO/P/2023/0160A patent/JOP20230160A1/ar unknown
- 2023-07-24 CL CL2023002163A patent/CL2023002163A1/es unknown
- 2023-07-25 EC ECSENADI202356223A patent/ECSP23056223A/es unknown
- 2023-07-25 CO CONC2023/0009803A patent/CO2023009803A2/es unknown
- 2023-07-25 DO DO2023000142A patent/DOP2023000142A/es unknown
-
2024
- 2024-02-28 US US18/590,300 patent/US20240279224A1/en active Pending
- 2024-05-22 CL CL2024001535A patent/CL2024001535A1/es unknown
-
2025
- 2025-06-25 JP JP2025107301A patent/JP2025160175A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20230323A (es) | Quinolinas y azaquinolinas como inhibidores de cd38 | |
| CL2020002821A1 (es) | Piridazinonas como inhibidoras de parp7. | |
| CL2021000084A1 (es) | Inhibidores de pd-1/pd-l1 | |
| CO2020009861A2 (es) | Inhibidores pd-1/pd-l1 | |
| MX2020012204A (es) | Inhibidores de kras g12c para tratar el cáncer. | |
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| CL2022000923A1 (es) | Heterociclos bicíclicos como inhibidores de fgfr. | |
| CO2022001453A2 (es) | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 | |
| CL2019002304A1 (es) | Compuestos para el tratamiento del cáncer. | |
| CL2019002895A1 (es) | Inhibidores de pd-1/pd-l1. | |
| CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
| MX2024012801A (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| MX394062B (es) | Métodos para el tratamiento del cáncer ovárico. | |
| CL2017002494A1 (es) | Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer | |
| CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
| ECSP18094983A (es) | Derivados de pirazol como inhibidores de la calicreína plasmática | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CY1124613T1 (el) | Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης | |
| CL2016001082A1 (es) | Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa | |
| CL2023000892A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional). | |
| DOP2018000238A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| CL2023002812A1 (es) | Combinaciones farmacéuticas para el tratamiento del cáncer | |
| CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
| CO2021014351A2 (es) | Derivados de quinolina y su uso para el tratamiento del cáncer | |
| MX2024003832A (es) | Nanoparticulas para el tratamiento del cancer. |